

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Touyun Biotech Group Limited**  
**透雲生物科技集團有限公司**  
*(Incorporated in Bermuda with limited liability)*  
**(Stock Code: 1332)**

**GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**” and individually, a “**Director**”) of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that on 25 April 2022, the Company granted share options (the “**Options**”) under the share option scheme of the Company adopted on 18 May 2012 (the “**Share Option Scheme**”) to employees (eligible participants as defined in the rules of the Share Option Scheme) (the “**Grantees**”) to subscribe for a total of 14,314,750 ordinary shares of HK\$0.04 each in the capital of the Company (the “**Shares**”), subject to acceptances by the Grantees. Details of the share options granted are set out as follows:

- Date of grant : 25 April 2022
- Exercise price of the Options granted : Each Option shall entitle the holder of the Option to subscribe for one Share upon exercise of such Option at an exercise price of HK\$1.34 per Share, which is higher than the highest of:
- (a) the closing price of HK\$0.90 per Share as quoted on the Stock Exchange on the date of grant;
  - (b) the average closing price of HK\$0.92 per Share as quoted on the Stock Exchange for the 5 consecutive trading days immediately preceding the date of grant; and
  - (c) the nominal value of a Share of HK\$0.04.

- Number of the Options granted : 14,314,750 Options, each Option shall entitle the Grantee to subscribe for one Share
- Closing price of the Shares on the date of grant : HK\$0.90 per Share
- Vesting date of the Options : The Options will be vested to the Grantees on 25 April 2023.
- Validity period of the Options : 4,314,750 Options are exercisable for a period of 3 years from 25 April 2023 to 24 April 2026 (both days inclusive); and
- 10,000,000 Options are exercisable for a period of 4 years from 25 April 2023 to 24 April 2027 (both days inclusive) according to the following vesting schedule:
- (i) 25% of the Options shall be exercisable from 25 April 2023 to 24 April 2027;
  - (ii) 25% of the Options shall be exercisable from 25 April 2024 to 24 April 2027;
  - (iii) 25% of the Options shall be exercisable from 25 April 2025 to 24 April 2027; and
  - (iv) 25% of the Options shall be exercisable from 25 April 2026 to 24 April 2027.

The Grantee is neither a director, chief executive or substantial shareholder of the Company nor an associate (as defined under the Listing Rules) of any of them.

By order of the Board  
**Touyun Biotech Group Limited**  
**Wang Liang**  
*Chairman*

Hong Kong, 25 April 2022

*As at the date of this announcement, the Board comprises the following directors:*

*Executive Directors*

Mr. Wang Liang (*Chairman*)  
Mr. Du Dong

*Non-executive Directors*

Mr. Chen Hui  
Ms. Tian Yuze  
Mr. Jia Wenjie  
Mr. Zhang Lele

*Independent Non-executive Directors*

Mr. Cheung Wing Ping  
Mr. Ha Kee Choy Eugene  
Mr. To Shing Chuen  
Mr. Hu Guohua